

CURRICULUM VITAE**Mary W. Redman, Ph.D.**

Current Address: Fred Hutchinson Cancer Research Center
1100 Fairview Avenue N., M2-B230
Seattle, WA 98109-1024

Phone: Office: (206) 667-4767

E-mail: mredman@fredhutch.org

Education: University of Washington, B.S. (Mathematics), 1997
University of Washington, M.S. (Biostatistics), 2000
University of Washington, Ph.D. (Biostatistics), 2004

POSITIONS

Associate Member, Fred Hutchinson Cancer Research Center, 2013 – present
Assistant Member, Fred Hutchinson Cancer Research Center, 2005 – 2013
Postdoctoral Fellow, University of Washington, 2004 – 2005
Staff Scientist, International AIDS Research and Training Program, University of Washington, 2004 – 2005
Statistical Consultant, United States Department of Veteran Affairs, 2000 – 2005
Research/Teaching Assistant, International AIDS Research and Training Program, University of Washington, 2002-2004
Statistical Consultant, School of Dentistry, University of Washington, 2002
Statistical Consultant, Qiagen Genomics, Bothell, Washington, 1999 – 2000
Research Assistant, HPV Research Group, University of Washington, 1997 – 2002

STATISTICAL INTERESTS

Clinical trial designs for assessment and discovery of predictive biomarkers of targeted agents. Interim monitoring considerations for hybrid designs. Applications of causal inference methods and techniques to clinical trials; assessment of prognostic and predictive factors.

PROFESSIONAL SOCIETY/NATIONAL INSTITUTE ROLES

American Association for Cancer Research (2008-present)

American Society of Clinical Oncology (2011 – present)
Education committee 2010-2013
Organizer/speaker education session 2012 meeting on Adaptive Trial Designs
Organizer/speaker education session 2013 meeting on Trial design in the acquired resistance setting
Young investigators fellowship committee 2012 - 2015

American Statistical Association (2002-present)

International Association for the Study of Lung Cancer (2008-present)
Education committee 2010 – 2013

International Biometrics Society (2002-present)
Treasurer WNAR 2009-present

Southwest Oncology Group (2005-present)
Lead Statistician, Lung committee 2005- present
Lead statistician, Lung-MAP Trial, 2013-present

Coltman Young Investigator Fellowship selection committee 2008- present
Nominating committee for chair and group statistician, 2011-2012

Thoracic Malignancy Steering Committee 2012

Member, Scientific Advisory Panel RFA-CA-08-026, *Pediatric Brain Tumor Consortium (U01)*

PROFESSIONAL SERVICE

Local Service

Member, FHCRC Scientific Review, Committee. 2013-present

Member, FHCRC Institutional Review Board, Committee C. June 2008-2013

Member, Data Safety Monitoring Committee, A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas, FHCRC

Member, Data Safety Monitoring Committee, Phase II study of the combination of high-dose methotrexate (HD-MTX) and intrathecal liposomal cytarabine (IT Depocyt) in patients with parenchymal and eptomeningeal metastases from breast cancer, FHCRC

Teaching/Supervising

University of Washington, Biost 511 guest lecturer. Spring 2006-2008.

University of Washington, Epi 586 guest lecturer, Fall 2005-2012.

Supervise Research Assistant, Dept. of Biostatistics, University of Washington, June 2006 – June 2007.

Journal Reviewer

Cancer Prevention and Research

Clinical Cancer Research

Clinical Lung Cancer

Associate editor, 2011-present

Epidemiology

International Journal of Biostatistics

International Journal of Cancer

Journal of Thoracic Oncology

Quality of Life Research

Statistics in Medicine

BIBLIOGRAPHY

Publications in refereed journals:

1. Gottlieb GS, Sow PS, Hawes SE, Ndoye I, **Redman M**, Coll-Seck AM, Faye-Niang MA, Diop A, Kuypers JM, Critchlow CW, Respass R, Mullins JI, Kiviat NB: Equal plasma viral loads predict a similar rate of CD4+ T Cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. *J Infect Dis* 185(7):905-914, 2002.
2. Brumback BA, Greenland SG, **Redman MW**, Kiviat N, Diehr, P: The intensity-score approach to adjusting for confounding. *Biometrics* 59(2):274-285, 2003.
3. Casper C, **Redman MW**, Huang ML, Pauk J, Lampinen TM, Hawes SE, Critchlow CW, Morrow RA, Corey L, Kiviat N, Wald A: HIV infection and human herpesvirus 8 (HHV-8) oral shedding among men who have sex with men. *J Acquir Immune Defic Syndr* 35(3):233-238, 2004.

4. Farquhar C, Rowland-Jones S, Mbori-Ngacha D, **Redman M**, Lohman B, Slyker J, Otieno P, Obimbo E, Rostron T, Ochieng J, Oyugi J, Bosire R, John-Stewart G: Human leukocyte antigen (HLA) B*18 and protection against mother-to-child HIV-1 transmission. *AIDS Res Hum Retroviruses* 20(7):692-697, 2004.
5. Farquhar C, Mbori-Ngacha D, **Redman M**, Bosire RK, Lohman BL, Piantadosi AL, Goodman RB, Ruzinski JT, Emery SR, Crudder CH, Overbaugh JM, John-Stewart GC: CC and CXC chemokines in breast milk are associated with mother-to-child HIV-1 transmission. *Current HIV Research* Oct;3(4):361-9, 2005.
6. Moinpour CM, Donaldson GW, **Redman MW**: Do general dimensions of quality of life add clinical value to symptom data? *J Natl Cancer Inst Monogr* 37:31-38, 2007. PMID: 17951229
7. **Redman M**, Crowley J: Small randomized trials. *J Thorac Oncol* 2(1):1-2, 2007. PMID: 17410001
8. Thompson IM, Jr, Lucia MS, **Redman MW**, Darke A, La Rosa FG, Parnes HL, Lippman SM, Coltman CA: Finasteride decreases the risk of prostatic intraepithelial neoplasia. *J Urol* 178:107-110, 2007. PMID: 17499284
9. Moinpour CM, Hayden KA, Unger JM, Thompson IM, Jr, **Redman MW**, Canby-Higano ED, Higgins BA, Sullivan JW, Lemmon D, Breslin S, Crawford ED: Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. *J Clin Oncol* 26(1):112-120, 2008. PMID: 18165645
10. Lara PN, Jr, **Redman MW**, Kelly K, Edelman MJ, Williamson SK, Crowley JJ, Gandara DR: Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. *J Clin Oncol* 26(3):463-467, 2008. PMID: 18202421
11. **Redman MW**, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Jr, Thompson IM: Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. *Cancer Prev Res* 1(3):174-181, 2008. PMCID: PMC2844801
12. Mack PC, **Redman MW**, Chansky K, Williamson SK, Farneth NC, Lara PN, Franklin WA, Le QT, Crowley JJ, Gandara DR: Lower osteopontin plasma levels are associated with superior outcomes following platinum-based chemotherapy in advanced non-small cell lung cancer patients: Southwest Oncology Group Trial S0003. *J Clin Oncol*. 2008 Oct 10;26(29):4771-6. Epub 2008 Sep 8. PMCID: PMC2653139
13. Misono S, Weiss N, Fann J, **Redman M**, and Yueh B: Incidence of Suicide in a National U.S. Cancer Registry. *J Clin Oncol*. 2008 Oct 10;26(29):4731-8. Epub 2008 Aug 11. PMCID: PMC2653137
14. Shepherd B, **Redman MW**, and Ankerst DP: The Causal Effect of Finasteride on the Severity of Prostate Cancer. *JASA* December 2008, 103 (484): 1392-1404. PMID: 22628357
15. Lara PN, Natale R, Crowley JC, Lenz HJ, **Redman MW**, Carleton J, Jett J, Langer C, Kuebler P, Dakhil S, Chansky K, and Gandara DR: Randomized Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results from Southwest Oncology Group Trial S0124. *J Clin Oncol*. 2009 May 20;27(15):2530-5. PMCID: PMC2684855
16. Le QT, Moon J, **Redman M**, Williamson SK, Lara PN Jr, Goldberg Z, Gaspar LE, Crowley JJ, Moore DF Jr, Gandara DR: Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic

- radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. *J Clin Oncol*. 2009 Jun 20;27(18):3014-9. Epub 2009 Apr 13. PMID: PMC2702233
17. Lara PN Jr, Chansky K, Shibata T, Fukuda H, Tamura T, Crowley J, **Redman MW**, Natale R, Saijo N, Gandara DR: Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer1: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124. *Cancer*. 2010 Aug 24. [Epub ahead of print] PMID: PMC2994945
 18. Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Shaker SR, Albain KS, Kim ES, **Redman MW**, Crowley JJ, Gandara DR: Southwest Oncology Group Study S0342: Phase II Selection Design Trial of Concurrent Chemotherapy and Cetuximab versus Chemotherapy Followed by Cetuximab in Advanced Stage Non-Small Cell Lung Cancer. *J Clin Oncol*. 2010 Nov 1;28(31):4747-54. Epub 2010 Oct 4. PMID: PMC3020704
 19. Moinpour CM, Vaught NL, Goldman B, **Redman MW**, Philip PA, Millwood B, Lippman SM, Seay TE, Flynn PJ, O'Reilly EM, Rowland KM, Wong RP, Benedetti J, Blanke CD: Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer. *J Clin Oncol* 28(22): 3611-6, 2010. PMID: PMC2917316.
 20. Tsao AS, Garland L, **Redman M**, Kernstine K, Gandara D, Marom EM: A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma by RECIST and modified RECIST criteria. *J Thorac Oncol*. 2011 Mar; 6(3):598-601. PMID: PMC3643692
 21. Garland LL, Chansky K, Wozniak AJ, Tsao AS, Gadgeel SM, Verschraegen CF, Dasilva MA, **Redman M**, Gandara DR: Phase II study of cedirinib in patients with malignant pleural mesothelioma: SWOG S0509. *J Thorac Oncol*. 2011 Nov; 6(11): 1938-1945. PMID: PMC3477852
 22. Lara PM and **Redman MW**: The Hazards of Randomized Phase II Trials. *Ann Oncol*. 2012 Jan;23(1):7-9 PMID: 22190670
 23. Qi Y, Allen Ziegler AL, Hillman SL, **Redman MW**, Schild SE, Gandara DR, Adjei AA, Mandrekar SJ: Impact of Disease Progression Date Determination on Progression-free Survival Estimates in Advanced Lung Cancer. *Cancer* 2012 Mar 20. doi: 10.1002/cncr.27528. [Epub ahead of print] PMID: PMC3481159
 24. Chen Y, Moon J, Pandya KJ, Lau DH, Kelly K, Hirsch FR, Gaspar LE, **Redman M**, Gandara DR: A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Lung Cancer. *Front Oncol* 3:219, 2013. PMID: PMC375267.
 25. **Redman MW**, Crowley JJ., Herbst RS, Hirsch FR, Gandara, DR: Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819. *Clin Cancer Res*. 2012 Aug 1;18(15):4004-12. Epub 2012 May 16. PMID: PMC3409929
 26. Gandara DR, Lara PN, Mack PC, Kelly K, Li T, Miyamoto S, Goodwin N, Beckett L, **Redman MW**: Algorithm for Co-Development of New Drug-Predictive Biomarker Combinations: Accounting for Inter- and Intra-patient Tumor Heterogeneity. *Clin Lung Cancer*. 2012 Sep;13(5):321-5. Epub 2012 Jun 6. No abstract available. PMID: PMC4049356
 27. McGregor BA, Syrjala, KL, Langer SL, Dolan ED, **Redman MW**: The Effect of Pre-Transplant Distress on Immune Reconstitution among Adult Hematopoietic Cell Transplantation Patients. *Brain Behav Immun*. 2012 Aug 13. pii: S0889-1591(12) PMID: PMC3549315

28. Lau DH, Moon J, Davies AM, Sanborn RE, Hirsch FR, Franklin WA, Ruzich JC, **Redman MW**, Gandara DR: Southwestern Oncology Group Phase II Trial (S0526) of Pemetrexed in Bronchioloalveolar Carcinoma Subtypes of Advanced Adenocarcinoma. *Clin Lung Cancer*. 14(4): 351-5, 2013. PMID: 23415808
29. **Redman MW**, Goldman BH, Leblanc M, Schott A, Baker LH: Modeling the Relationship between Progression-Free Survival and Overall Survival: The Phase II/III Trial. *Clin Cancer Res*. 2013 May 15;19(10):2646-56. doi: 10.1158/1078-0432.CCR-12-2939. PMCID: PMC4131693.
30. Kim ES, Moon J, Herbst RS, **Redman MW**, Dakhil SR, Velasco MR, Hirsch FR, Mack PC, Kelly K, Gandara DR: Phase II Trial of Combination Carboplatin, Paclitaxel, Cetuximab and Bevacizumab Followed by Cetuximab and Bevacizumab in Patients with Advanced Non-Small Cell Lung Cancer: SWOG S0536. *J Thorac Oncol*. 2013 Dec;8(12):1519-28. Doi: 10.1097/JTO.000000000000009. PMCID: PMC4072123
31. Gandara DR, Li T, Lara PN, Kelly K, Riess JW, **Redman MW**, Mack PC: Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. *Clin Lung Cancer*. 2014 Jan;15(1):1-6. Doi: 10.1016/j.clc.2013.10.001. Epub 2013 Oct 12. PMID: 24176733 [PubMed – in process].
32. Bepler G, Zinner RG, Moon J, Calhoun R, Kernstine K, Williams CC, Mack PC, Oliveira V, Zheng Z, Stella PJ, **Redman MW**, Gandara DR: A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). *Cancer* 120(15): 2343-51, 2014. PMCID: PMC4140446.
33. Allen JW, Moon J, **Redman M**, Gadgeel SM, Kelly K, Mack PC, Saba HM, Mohamed MK, Jahanzeb M, Gandara DR: Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. *J Clin Oncol* 32(23): 2463-70, 2014. PMCID: PMC4121504 [Available on 2015/08/10].
34. Venook AP, Arcila ME, Benson AB 3rd, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, **Redman MW**, Stearns V, McClure J, Birkeland ML: NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. *J Natl Compr Canc Netw* 12(11): 1629-49, 2014. PMID: 25361808
35. Lara PN Jr, Moon J, **Redman MW**, Semrad TJ, Kelly K, Allen JW, Gitlitz BJ, Mack PC, Gandara DR: Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. *J Thrac Oncol* 10(1): 110-5, 2015. PMCID: PMC4320001 [Available on 2016/01/01].
36. Innovative Clinical Trials: The LUNG-MAP Study. Steuer CE1, Papadimitrakopoulou V, Herbst RS, **Redman MW**, Hirsch FR, Mack PC, Ramalingam SS, Gandara DR. *Clin Pharmacol Ther*. 2015 May;97(5):488-91. doi: 10.1002/cpt.88.
37. Herbst RS, Gandara DR, Hirsch FR, **Redman MW**, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA: Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for

Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. PMID: 25680375.

38. **Redman MW** and Allegra C. The Master Protocol Concept. *Seminars in Oncology* (special invited issue: Progress and Infrastructure for Clinical Research: The NCI National Clinical Trials Network; guest editor: CD Blanke), in press.
39. Foster NR, Renfro LA, Schild SE, **Redman MW**, Wang XF, Dahlberg SE, Ding K, Bradbury PA, Ramalingam SS, Gandara DR, Shibata T, Saijo N, Vokes EE, Adjei AA, Mandrekar SJ. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. *J Thorac Oncol*. 2015 Jul;10(7):1099-106. PMID: 26134227
40. McGregor BA, Dolan ED, Murphy KM, Sannes TS, Highland KB, Albano DL, Ward AA, Charbonneau AM, **Redman MW**, Ceballos RM. Cognitive Behavioral Stress Management for Healthy Women at Risk for Breast Cancer: a Novel Application of a Proven Intervention. *Ann Behav Med*. 2015 Aug 20. [Epub ahead of print] PMID: 26290001

Book Chapters

1. **Redman MW** and Crowley JJ. Clinical Trials Design. In: Shields TW, LoCicero III J, Reed CE, Geins RH, eds. *General Thoracic Surgery*, 7th ed.
2. **Redman MW**. Early Stopping in Cancer Clinical Trials. In: *Handbook of Statistics in Oncology*. Eds. Crowley JJ and Hoering A. 3rd ed. 2012.
3. Mandrekar SJ, **Redman MW**, and Billingham LJ. Methodology of Clinical Trials in Lung Cancer: Design and Endpoint Considerations. In: *The IASLC Multidisciplinary Approach to Thoracic Oncology*. Eds. Pass H and Scagliotti G. In press.